History of Formation

Affitech was established in 1997 by a group of Norwegian and German scientists on the basis of the acquisition of the worldwide exclusive rights from German Cancer Center, Heidelberg, Germany of “Breitling “ IP which covered phagemid display of human antibodies.

In May 2009, Affitech AS was combined with Pharmexa A/S to form Affitech A/S resulting in the company now being listed on the Nasdaq OMX Copenhagen exchange.